Biology of Aging. Faculty Disclosure. Learning Objectives. I have no relevant financial disclosures relative to the content of this presentation.

Similar documents
Aging Changes That Impact Medication Management

Geriatric Pharmacology

2/25/2015 PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY OVERALL PRESCRIBING

Prescribing Drugs to the Elderly

2/26/2015 PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY

Geriatric Pharmacology. Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center

Pharmacology in the Elderly

Can PK and Modelling Help?

Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

Potential Drug Dosing Variability in Women. Jim Beaulieu, PharmD Senior Clinical Pharmacist Specialist Rhode Island Hospital and The Miriam Hospital

Variation in drug responses & Drug-Drug Interactions

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

2/25/2016. Pharmacodynamics of Aging Narrowing of the Therapeutic Index in the Face of Therapeutic Opportunity. Educational Objectives

Pharmacodynamics of Aging Narrowing of the Therapeutic Index in the Face of Therapeutic Opportunity

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy

Aging and Geriatric Assessment March 31, 2008 Sharon Leigh, Pharm D. BCPS Providence ElderPlace

Family Medicine for English language students of Medical University of Lodz. Seminar 12. Elderly care. Przemysław Kardas MD PhD

Pharmacokinetics PCTH 325. Dr. Shabbits September 12, C t = C 0 e -kt. Learning Objectives

Pharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core

Prescribing and Pharmacokinetic Considerations in the Elderly

There s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients

Physical and Sensory Changes in the Older Adult: Considerations for Medication Management

Frailty: from Academic Definition to Clinical Applicability

Orientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology

Drug dosing in Extremes of Weight

The role of medication in falls risk

How Does Aging Mechanistically Contribute to Heterogeneity of Treatment Effects?

OBJECTIVES. Key issues in geriatric pharmacology. Effects of age on pharmacokinetics and pharmacodynamics

Levocetirizine dihydrochloride

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne

Industrial Toxicology

A. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention

Pharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen

DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA

Rational Pharmacotherapy for LUTS in Older People. Dr William Gibson MBChB MRCP

Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

Anxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Safe Medication Use. Holly Divine, PharmD, CGP, CDE. University of Kentucky College of Pharmacy Department of Pharmacy Practice & Science

National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL or FAX

PHARMACOTHERAPY IN THE OLDER PERSON NAMIRAH JAMSHED M.B;B.S ASSOCIATE PROFESSOR UTSW MEDICAL CENTER DALLAS

PRESCRIBING IN LIVER AND RENAL DISEASE

Geriatrics and Cancer Care

Definition and Statistics

Geriatric Alterations Associated with Neurological Conditions

Slide 1. Slide 2. Slide 3. Drug Action and Handling. Lesson 2.1. Lesson 2.1. Drug Action and Handling. Drug Action and Handling.

FRAILTY AND COGNITION IN THE ASSESSMENT OF VASCULAR SUGERY PATIENTS WHY WHY DISCLOSURES. INDIVIDUAL None. INSTITUTIONAL Cook, Inc

Chitra Fernando, MD March 18, 2008

CHAPTER 2. GERIATRICS, SELF-ASSESSMENT QUESTIONS

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National

Anxiety Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM

Renal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology

4/26/2012. Laura Grooms, MD Assistant Professor Geriatric Medicine Department of Family and Geriatric Medicine University of Louisville April 20, 2012

Benzodiazepines: Comparative Effectiveness and Strategies for Discontinuation. Ann M. Hamer, PharmD, BCPP Rural Oregon Academic Detailing Project

The Industry s Views on Older Old Patients

Frailty. Nicholas Butler MD, MBA Department of Family Medicine University of Iowa

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

PHA First Exam Fall 2003

Richard A. Beers, M.D. Professor, Anesthesiology SUNY Upstate Medical Univ VA Medical Center Syracuse, NY

FRAILTY SYNDROME. dr. Rose Dinda Martini, Sp.PD, K-Ger

Pharmacotherapy Issues in the Pediatric Population

Chapter Questions. Modern Pharmacology With Clinical Applications. Sixth Edition

Effects of Liver Disease on Pharmacokinetics

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK

How to Teach About Drugs and Aging

Principles of Drug Action. Intro to Pharmacology: Principles of Courework Drug Action Intro to Pharmacology

Prescribing in the Elderly: Ins and Outs of PIMs. April 8, 2016 Ronan Factora, MD Center for Geriatric Medicine

MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride

Frailty and Cognitive Dysfunction in Heart Failure. Disclosures. Frailty 5/24/2017. I have no disclosures relevant to this presentation

Effects of Renal Disease on Pharmacokinetics

Renal Impairment From Dettli to Guideline: What can we learn?

Geriatric Assessment & Intervention. The Goal 5/9/2017. Current events. Student Conclave 2017 Fresno State goo.gl/slides/m5d6wm.

BACKGROUND Measuring renal function :

Prescribing for older people

Ideal Sedative Agent. Benzodiazepines 11/12/2013. Pharmacology of Benzodiazepines Used for Conscious Sedation in Dentistry.

Ideal Sedative Agent. Pharmacokinetics. Benzodiazepines. Pharmacodynamics 11/11/2013

Principles of Medication Use in Older Adults ANNE L. HUME, PHARMD PROFESSOR OF PHARMACY UNIVERSITY OF RHODE ISLAND

public health crisis! Understanding frailty at population level!

Benzodiazepines. Benzodiazepines

Prevention of Medication-Related Falls Through Appropriate Medication Use. Clay Sprouse, MEd., CPhT Piedmont Technical College

Pharmacotherapy In Geriatrics: Cause For Concern

Medication Management. Medications: The Right Balance. Who are we talking about? Geriatric Syndromes 9/19/2016. Older adults are a heterogenous group!

Drug Disposition in Obesity & Protein-Calorie Malnutrition

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

TRAPADOL INJECTION FOR I.V./I.M. USE ONLY

Excretion of Drugs. Prof. Hanan Hagar Pharmacology Unit Medical College

Nutrition to prevent and treat sarcopenia in older people

A Geriatrician s Perspective on Successful Aging. Ariel Green, MD, MPH Assistant Professor of Medicine

Pharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist

Tranquilizers & Sedative-Hypnotics

Nutrition in the critically ill elderly (geriatric) patient CHRISTINA NIEUWOUDT RD(SA) SASPEN/CCSSA CONGRESS 2017

An approach to prescribing in the elderly. Preamble

Pharmacokinetics. Karim Rafaat

Acilight 75mg Tablets. Ranitidine Hydrochloride 83.57mg eq.to Ranitidine 75mg. Generic Name: Ranitidine Hydrochloride 83.57mg eq.

The Deconditioned Elderly Patient: Have We Been Getting it Wrong? By: Ernest Roy PT, DPT

Polypharmacy & De-prescribing In Older Adults

Transcription:

Biology of Aging Aging Changes That Impact Medication Management Emily P. Peron, PharmD, MS, BCPS, FASCP Assistant Professor of Geriatrics Virginia Commonwealth University School of Pharmacy Richmond, VA, USA Faculty Disclosure I have no relevant financial disclosures relative to the content of this presentation. Learning Objectives At the conclusion of this application-based activity, participants should be able to: 1. Recognize the physiological heterogeneity of the older adult population. 2. Recognize the spectrum of aging from healthy aging to frailty. 3. Compare and contrast age-related physiologic changes versus pathophysiologic changes in older adults. 4. Evaluate the impact of age-related pharmacokinetic/ pharmacodynamic changes on drug disposition in older adults. 5. Apply the knowledge of physiologic changes associated with aging to the clinical use of medications, including PK/PD changes.

Audience Participation How do you define the aging population? The Aging Process Aging is a pattern of life changes that occurs as one grows older Gerontology is the study of individual and collective aging processes Biological age Psychological age Social age Legal age Functional age

Is Aging Synonymous with Disease? Aspects of the aging process make us more vulnerable to illness and disease However, no pathology is inevitable with age! Physical changes once attributed to aging are now recognized as being related to lifestyle choices Normative Aging Series of time-dependent anatomic and physiologic changes that reduce physiologic reserve and functional capacity Aging = reduced tissue/physiological function Aging = increased susceptibility to disease Aging = decreased resistance to stress VISION HEARING SMELL TASTE Normative Biological Changes Non-Normative Biological Changes Presbyopia occurs in the 40s and can be corrected with glasses Subtle changes usually begin in the 40s and progress gradually with age Loss of high-frequency hearing may decrease ability to recognize speech Odor identification may be less efficient, likely due to environmental factors and olfactory receptors not being replaced as completely as younger adults Incidence of macular degeneration, glaucoma, and cataracts may increase with age, but none are considered normal aging Tinnitus may be the result of certain diseases or medications Significant hearing loss occurs as a result of damage to ear structure Loss of smell (and likely taste) can occur as a result of upper respiratory infections, head trauma, nasal or sinus diseases Noticeable decrease in sense of taste is Dry mouth is the result of decreased saliva reported around age 60-70 as taste production receptors change Research is limited, but changes in touch and skin receptors is thought to take place TOUCH/SKIN gradually. There may be some loss of receptors over time, so more stimulation may be required to elicit a response. Saxon SV, Etten MJ, Perkins EA. Physical change & aging: A guide for the helping professions. 2 nd ed. New York, NY: Springer Publishing Company; 2015.

Frailty A clinical syndrome in which 3 or more of the following criteria are present: Unintentional weight loss (10 lbs in the past year) Self-reported exhaustion Weakness (grip strength) Slow walking speed Low physical activity Frail older adults are at increased risk of falls, worsening mobility or ADL disability, hospitalization, and death Fried LP, et al. J Gerontol A Biol Sci Med Sci. 2001;56:M146-56.

http://guidelines.diabetes.ca/app_themes/cdacpg/images/ch37_fig1_clinical_frailty_scale.jpg Possible Trajectories of Physiologic Reserve During Aging Calvani R, Marini F, Cesari M, et al. J Cachexia Sarcopenia Muscle. 2015;6:278-86. http://www.psychiatrictimes.com/site s/default/files/figures_diagrams/ptjac obsoncmefig1.jpg

Audience Participation Which pharmacokinetic parameter is LEAST affected by age-related physiological changes? a) Absorption b) Distribution c) Metabolism d) Excretion Audience Participation Which benzodiazepines are preferred among older adults? a) Lorazepam, oxazepam, temazepam b) Diazepam, flurazepam, triazolam c) Alprazolam, clonazepam, lorazepam d) Clorazepam, midazolam, triazolam Absorption Physiological Change gastric ph gastric acid secretion gastrointestinal blood flow gastric surface area gastrointestinal motility Pharmacokinetic Consequences Potential for delay in absorption, but no significant change in extent of absorption for most drugs Exception: increased gastric ph decreased absorption of calcium carbonate, increased risk of constipation Mitchell SJ, Kane AE, Hilmer SN. Current Gerontol Geriatr Res. 2011;624156. https://www.merckmanuals.com/professional/geriatrics/drug-therapy-in-the-elderly/pharmacokinetics-in-the-elderly

Absorption: Take-Home Message Most drugs are well-absorbed in the presence of age-related changes only Age-related changes as well as concurrent diseases result in increased variability in drug absorption Effects of aging on absorption from other sites of administration are poorly understood Distribution Physiologic Change Volume of Distribution (Vd) Effect Examples body water Vd for hydrophilic drugs ethanol, lithium lean body mass Vd for drugs that bind to muscle digoxin fat stores Vd for lipophilic drugs diazepam albumin % of unbound or free drug valproic acid, phenytoin, warfarin Shi S et al. Curr Drug Metab. 2011;12:601-10. Vestal RE et al. Clin Pharmacol Ther. 1977;21:343-54. Distribution: Take-Home Message Distribution may be altered due to age-related physiologic changes and concurrent diseases Lipid-soluble drugs may show an increased volume of distribution while water-soluble drugs may show a decreased volume of distribution Age-related changes in protein binding do not generally result in clinically significant changes in drug therapy

Metabolism Physiological Change hepatic blood flow hepatic mass CYP450 content Pharmacokinetic Consequences Phase I metabolism may be impaired/prolonged Phase II metabolism in fit older adults in frail older adults ( first-pass metabolism) Mitchell SJ, Kane AE, Hilmer SN. Current Gerontol Geriatr Res. 2011;624156. Metabolism Pathway Effect Examples Phase I: oxidation, hydroxylation, dealkylation, reduction Phase II: glucuronidation, conjugation, or acetylation Conversion to metabolites of lesser, equal, or greater Conversion to inactive metabolites diazepam, quinidine, piroxicam, theophylline lorazepam, oxazepam, temazepam Metabolism: Take-Home Message For oxidatively metabolized drugs, doses should generally be reduced then adjusted based on patient response and tolerability Drugs metabolized exclusively by Phase II mechanisms are preferred Potential for significant drug interactions, particularly resulting from hepatic enzyme inhibition in patients on multiple medications, must be carefully considered

Excretion Physiological Change renal blood flow glomerular filtration rate tubular secretion Pharmacokinetic Consequences Renal elimination of drugs can be impaired, thus altering drug t½ Mitchell SJ, Kane AE, Hilmer SN. Current Gerontol Geriatr Res. 2011;624156. Excretion Cl cr (140 age) 62 72 1.3 Estimated CrCl Age 45 = 63 ml/min Age 65 = 50 ml/min Age 85 = 36 ml/min Digoxin t½ = 38-48 hours in patients with normal renal function 69 hours on average in older adults Ranitidine Usual treatment dose: 150 mg twice daily or 300 mg daily CrCl < 50mL/min 150 mg every 24 hours Excretion: Take-Home Message Decreased renal clearance of drugs is the most significant age-related change in PK, accounting for the majority of necessary dose adjustments Serum creatinine may be a poor predictor of renal function, especially in frail older adults

Pharmacodynamics Age-related changes in receptor responsiveness and homeostatic regulation may alter an older adult s response to drug therapy Changes in receptor number or affinity or changes in post-receptor response Impairment of physiologic and homeostatic mechanisms physiologic reserve baseline performance Slattum PW, Ogbonna KC, Peron EP. The Pharmacology of Aging. In: Fillit H, Rockwood K, Young J (editors). Brocklehurst s Textbook of Geriatric Medicine and Gerontology, 8 th Edition. Philadelphia, PA: Elsevier, Inc; 2017. Drugs Whose Sensitivity is Altered with Advancing Age B-agonists ( ) B-blockers ( ) Benzodiazepines ( ) Calcium antagonists ( ) Dopaminergic agents ( ) Furosemide ( ) H 1 -antihistamines ( ) Metoclopramide ( ) Neuroleptics ( ) Opioids ( ) Warfarin ( ) Vaccines ( ) Slattum PW, Ogbonna KC, Peron EP. The Pharmacology of Aging. In: Fillit H, Rockwood K, Young J (editors). Brocklehurst s Textbook of Geriatric Medicine and Gerontology, 8 th Edition. Philadelphia, PA: Elsevier, Inc; 2017. Pharmacodynamics Physiologic and homeostatic changes may affect drug responses, altering baseline performance and the ability to compensate for effects of medications Medications can also contribute to geriatric syndromes Medications that act on the CNS and cardiovascular system are of particular concern Potential for synergistic or additive effects from concurrent medication use exist Slattum PW, Ogbonna KC, Peron EP. The Pharmacology of Aging. In: Fillit H, Rockwood K, Young J (editors). Brocklehurst s Textbook of Geriatric Medicine and Gerontology, 8 th Edition. Philadelphia, PA: Elsevier, Inc; 2017.

Clinical Pharmacology Paradigm Pharmacokinetics Pharmacodynamics Efficacy Drug Concentration in the Circulation Drug Effect Desirable Therapeutic Outcome Absorption Distribution Metabolism Excretion Drug-receptor interactions Concentration at receptors Homeostatic mechanisms Compliance/ adherence Disease characteristics